Importantly, the FXa indirect inhibitor fondaparinux, which we found did not block FXa’s protective effects against SARS-CoV-2, has proven to be safe and effective for venous thrombosis prophylaxis in hospitalized COVID-19 patients22. The gene discussed is F10; the disease is COVID-19.